Agile Therapeutics partners with Afayxs to expand access to Twirla
Agile Therapeutics, Inc. recently announced a new alliance with Afaxys Pharma, LLC to promote levonorgestrel and ethinyl estradiol (Twirla) transdermal system.
Twirla is an effective, low-dose contraceptive option in a non-daily, non-invasive patch. It is a once-weekly patch that contains levonorgestrel and ethinyl estradiol.
The partnership will help Americans who rely on community and public health centers get access to Twirla. Afaxys is a leading provider of innovative contraceptive options, making this partnership strategic and beneficial for all in the US family planning community.
“Afaxys and Agile Therapeutics are aligned on a mutual goal to provide reliable, affordable contraceptive access to women on their sexual and reproductive health journeys,” said Ronda Dean, President, CEO & Co-Founder of Afaxys. “We are committed to community and public health patients and providers, and this alliance will empower women with one more reliable family planning option to consider as they work with their physicians to choose the method of contraception that is right for them.”1
“This strategic agreement with Afaxys, a recognized leader in the public health system, will help ensure that Twirla is available, accessible and affordable to a much broader group of patients who can benefit from it,” commented Al Altomari, Chairman and CEO of Agile Therapeutics. “We look forward to advancing women’s reproductive health together.”1
Reference
- Agile Therapeutics and Afaxys Partner to Expand Access to Twirla (Levonorgestrel and Ethinyl Estradiol) Transdermal System | Agile Therapeutics. Agile Therapeutics. Published 2022. Accessed January 23, 2022. https://ir.agiletherapeutics.com/news-releases/news-release-details/agile-therapeutics-and-afaxys-partner-expand-access-twirlar
Midlife sexual health boosts for nonheterosexual women reported
December 23rd 2024A recent study highlights improved sexual function and reduced distress among nonheterosexual women during menopause compared to their heterosexual counterparts, shedding light on how sexual identity impacts well-being.
Read More
Recap on reproductive rights with David Hackney, MD, MS
December 20th 2022In this episode of Pap Talk, we spoke with David Hackney, MD, MS, maternal-fetal medicine physician at Case Western Reserve University and chair of ACOG's Ohio chapter for a full recap of where restrictions on reproductive rights have been and where they're going.
Listen
In this episode of Pap Talk, Gloria Bachmann, MD, MSc, breaks down what it means to be a health care provider for incarcerated individuals, and explores the specific challenges women and their providers face during and after incarceration. Joined by sexual health expert Michael Krychman, MD, Bachmann also discusses trauma-informed care and how providers can get informed.
Listen
IUD placement within 48 hours nonsuperior vs 2 to 4 weeks after abortion
November 19th 2024A study reveals no significant difference in 6-month intrauterine device use between placements within 48 hours or 2 to 4 weeks after a second-trimester abortion, though earlier placement carries a higher expulsion risk.
Read More
